Outlook Therapeutics rises after US FDA accepts to review eye disease treatment

Outlook Therapeutics

16/06/2026 13:21

** Shares of Outlook Therapeutics OTLK.O rise 8.6% to $1.25 premarket 
** Drugmaker says the U.S. FDA has accepted for review its resubmitted marketing application for ONS-5010, branded as Lytenava, after the U.S. FDA declined to approve it in December
** OTLK's treatment, Lytenava, targets wet age-related macular degeneration, a common eye disease that causes vision loss due to leaking blood vessels in the retina
** The resubmission has been classified as a Class 1 review, with a target action date of July 29, co says
** Lytenava is a specific, officially authorized formulation of FDA-approved drug bevacizumab
** Up to last close, stock down 26.6% this year

 (Reporting by Siddhi Mahatole)
 ((siddhi.mahatole@thomsonreuters.com))